Registry of Patients Being Treated With Norditropin, Recombinant Human Growth Hormone

Trial Profile

Registry of Patients Being Treated With Norditropin, Recombinant Human Growth Hormone

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Somatropin (Primary)
  • Indications Dwarfism; Growth disorders; Short stature; Somatotropin deficiency
  • Focus Therapeutic Use
  • Acronyms ANSWER
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 11 Apr 2017 Status changed from recruiting to completed.
    • 20 Feb 2017 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.
    • 20 Feb 2017 Planned End Date changed from 1 Dec 2019 to 31 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top